ERBB2 and cancer: Margetuximab is an Fc (fragment crystallizable region) engineered HER2-directed monoclonal antibody with enhanced ADCC activity [38]; notably enough, promising antitumor activity has been reported in early-phase clinical trials on HER2-positive cancer patients, including low HER2-expressing GC [39].